Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark H N Corrigan
AddedFeb 15, 2024
UpdatedMay 31, 2026
Mark H N Corrigan

Mark H N Corrigan

Board Member, Epirus Biopharmaceuticals

CrunchbaseLinkedInThe Org

Mark H N Corrigan's Career

Epirus Biopharmaceuticals
Epirus Biopharmaceuticals

Boston, MA, US

Board Member· Board
Wave Life Sciences
Wave Life Sciences

Cambridge, MA, US

Board Member· Board
Trevena
Trevena

King of Prussia, PA, US

Board Member· Board
Pamlico Biopharma
Pamlico Biopharma

Oklahoma City, OK, US

Board Member· Board
Synereca Pharmaceuticals
Synereca Pharmaceuticals

Chapel Hill, NC, US

Board Member· Board
Quartet Medicine
Quartet Medicine

Cambridge, MA, US

Board Member· Board
BlackThorn Therapeutics
BlackThorn Therapeutics

San Francisco, CA, US

Board Member· Board
Tremeau Pharmaceuticals
Tremeau Pharmaceuticals

Concord, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark H N Corrigan's Career

Epirus Biopharmaceuticals
Epirus Biopharmaceuticals
Public$83.1M732000Boston, MA, US
Board Member· Board
Wave Life Sciences
Wave Life Sciences
Public$324M2172012Cambridge, MA, US
Board Member· Board

Leadership at Wave Life Sciences

Christian HenryChristian HenryBoard Member
Gregory L. VerdineGregory L. VerdineCo-Founder
Paul BolnoPaul BolnoCEO
Takeshi WadaTakeshi WadaCo-Founder
Ken TakanashiKen TakanashiBoard Member
Adrian RawcliffeAdrian RawcliffeBoard Member

Similar to Wave Life Sciences

Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Twist BioscienceTwist BioscienceSan Francisco, CA, USSynthetic DNAest. 2013Twist BioscienceSan Francisco, CA, US · est. 2013

Twist Bioscience: A leading US biotech firm specializing in synthetic DNA for diverse applications.

Public · $553.1M989
Orbital TherapeuticsOrbital TherapeuticsCambridge, MA, USMedicines, RNA Therapiesest. 2022Orbital TherapeuticsCambridge, MA, US · est. 2022

Orbital Therapeutics: Advancing global health with innovative RNA-based medicines.

Series A · $270M33
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
Trevena
Trevena
Public$473.7M352007King of Prussia, PA, US
Board Member· Board

Leadership at Trevena

Jake NunnJake NunnBoard Member
Howard RockmanHoward RockmanBoard Member
Scott BraunsteinScott BraunsteinBoard Member
Lonnie MoulderLonnie MoulderBoard Member
Carrie L. BourdowCarrie L. BourdowBoard Member
Robert LefkowitzRobert LefkowitzCo-Founder

Similar to Trevena

Tremeau PharmaceuticalsTremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Private Equity · $115.2M11
TrigeminaTrigeminaMoraga, CA, USPain Treatmentsest. 2006TrigeminaMoraga, CA, US · est. 2006

Trigemina, Inc.: A US-based pharmaceutical company innovating non-opiate pain therapies.

Series A · $27.6M11
Tris PharmaTris PharmaMonmouth Junction, NJ, USPharmaceuticalsest. 2000Tris PharmaMonmouth Junction, NJ, US · est. 2000

Tris Pharma, a New Jersey-based medical organization, innovates drug delivery technologies and medicines for disease treatment.

Public · $141.6M350
Neurana PharmaceuticalsNeurana PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2013Neurana PharmaceuticalsSan Diego, CA, US · est. 2013

Neurana Pharmaceuticals: A US-based specialty pharma company innovating treatments for CNS diseases.

Series A · $60M5
Pamlico Biopharma
Pamlico Biopharma
Series A$2.2M62011Oklahoma City, OK, US
Board Member· Board

Leadership at Pamlico Biopharma

Clayton I. DuncanClayton I. DuncanBoard Member

Similar to Pamlico Biopharma

IdbiologicsIdbiologicsNashville, TN, USAntibodies, Therapeuticsest. 2017IdbiologicsNashville, TN, US · est. 2017

IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.

Seed · $4.8M7
BioClonetics ImmunotherapeuticsBioClonetics ImmunotherapeuticsRockwall, TX, USAntibodies, Biopharmaceuticalsest. 2009BioClonetics ImmunotherapeuticsRockwall, TX, US · est. 2009

BioClonetics: A biotech firm developing and producing monoclonal antibodies to combat infectious diseases.

Public · $255.6k6
MicrobplexMicrobplexAtlanta, GA, USDiagnostic Platformsest. 2011MicrobplexAtlanta, GA, US · est. 2011

MicroBPlex develops diagnostic platforms using innovative antibodies to identify acute microbial infections.

Angel · $248.7k6
Plasmonic DiagnosticsPlasmonic DiagnosticsColumbia, MO, USDiagnostics, Testingest. 2015Plasmonic DiagnosticsColumbia, MO, US · est. 2015

Missouri-based Plasmonic Diagnostics offers precise solutions for detecting infectious, STDs, and cancer.

Angel · $224.9k1
Synereca Pharmaceuticals
Synereca Pharmaceuticals
Pre-Seed$2.3M62017Chapel Hill, NC, US
Board Member· Board

Leadership at Synereca Pharmaceuticals

Bennett LoveBennett LoveFounder
Quartet Medicine
Quartet Medicine
Series A$23M72013Cambridge, MA, US
Board Member· Board

Leadership at Quartet Medicine

Gerhard KoenigGerhard KoenigBoard Member
Bruce BoothBruce BoothBoard Member
Henry B. SkinnerHenry B. SkinnerBoard Member
John CreecyJohn CreecyBoard Member
Kevin PojasekKevin PojasekFounder
BlackThorn Therapeutics
BlackThorn Therapeutics
Acquired$138M02015San Francisco, CA, US
Board Member· Board

Leadership at BlackThorn Therapeutics

Lori HuLori HuBoard Member
Alex TkachenkoAlex TkachenkoFounder
Julie SunderlandJulie SunderlandBoard Member
George GolumbeskiGeorge GolumbeskiBoard Member
Kristina BurowKristina BurowBoard Member
Paul L. BernsPaul L. BernsBoard Member
Tremeau Pharmaceuticals
Tremeau Pharmaceuticals
Private Equity$115.2M112016Concord, MA, US
Board Member· Board

Leadership at Tremeau Pharmaceuticals

Brad SippyBrad SippyBoard Member

Mark H N Corrigan's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Mark H N Corrigan

Frank LongoFrank LongoFounder · PharmatrophixMark R. BamforthMark R. BamforthBoard Member · Continuus PharmaceuticalsFrank MorichFrank MorichBoard Member · Cue BiopharmaMike KishbauchMike KishbauchBoard Member · Astria Therapeutics